Legal & General Group
GLUE icon

Legal & General Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Legal & General Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$400K Buy
24,319
+20,074
+473% +$384K ﹤0.01% 2412
2025
Q4 		$66.6K Hold
4,245
– – ﹤0.01% 2675
2025
Q3 		$31.5K Hold
4,245
– – ﹤0.01% 2871
2025
Q2 		$19.1K Buy
4,245
+648
+18% +$2.89K ﹤0.01% 3020
2025
Q1 		$16.7K Hold
3,597
– – ﹤0.01% 3010
2024
Q4 		$25K Sell
3,597
-12,962
-78% -$97.3K ﹤0.01% 2952
2024
Q3 		$87.8K Buy
16,559
+756
+5% +$3.82K ﹤0.01% 2738
2024
Q2 		$59.1K Hold
15,803
– – ﹤0.01% 2774
2024
Q1 		$111K Sell
15,803
-4,365
-22% -$25.9K ﹤0.01% 2728
2023
Q4 		$114K Sell
20,168
-14,457
-42% -$56.7K ﹤0.01% 2753
2023
Q3 		$166K Buy
34,625
+6,469
+23% +$41.6K ﹤0.01% 2757
2023
Q2 		$193K Buy
28,156
+19,937
+243% +$129K ﹤0.01% 2741
2023
Q1 		$64K Buy
8,219
+781
+11% +$5.43K ﹤0.01% 2837
2022
Q4 		$56.6K Buy
7,438
+384
+5% +$3.2K ﹤0.01% 2932
2022
Q3 		$57K Buy
7,054
+130
+2% +$1.19K ﹤0.01% 2946
2022
Q2 		$67K Buy
6,924
+1,931
+39% +$19.4K ﹤0.01% 2946
2022
Q1 		$70K Buy
4,993
+1,676
+51% +$23.3K ﹤0.01% 2940
2021
Q4 		$68K Buy
3,317
+2,235
+207% +$46.8K ﹤0.01% 2978
2021
Q3 		$24K Sell
1,082
-1,918
-64% -$55K ﹤0.01% 3212
2021
Q2 		$69K Buy
+3,000
New +$61.1K ﹤0.01% 2853

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Legal & General Group's GLUE Position: Q1 2026 in Review

Legal & General Group increased its Monte Rosa Therapeutics (GLUE) stake by 473% in Q1 2026, buying an estimated $384K and bringing the position to 24,319 shares worth $400K. The position accounts for ﹤0.01% of the portfolio, ranked #2412.

Legal & General Group first reported a position in GLUE in Q2 2021 and has held it in 20 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Legal & General Group held 24,319 shares of Monte Rosa Therapeutics worth $400K as of Q1 2026.
  • Legal & General Group bought 20,074 Monte Rosa Therapeutics shares in Q1 2026, an estimated $384K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2412 holding.
  • Legal & General Group first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.